The ketogenic diet has been identified as a therapeutic anticancer agent, lowering serum insulin levels by upregulating β-hydroxybutyric acid levels in mouse models of BC, thereby inhibiting tumor progression and lung metastasis; when combined with rapamycin (mTOR inhibitor), it exhibits promising anti-tumor effects 184. The gene discussed is INS; the disease is neoplasm.